<?xml version="1.0" encoding="UTF-8"?>
<p id="p0085">Several approved HIV protease inhibitors (
 <bold>15</bold>, 
 <bold>16</bold>, and 
 <bold>18</bold>) were previously repurposed for the treatment of SARS (
 <xref rid="sch2" ref-type="fig">Scheme 2</xref> ).
 <xref rid="bib19" ref-type="bibr">19</xref>, 
 <xref rid="bib20" ref-type="bibr">20</xref>, 
 <xref rid="bib21" ref-type="bibr">21</xref> They were hypothesized to inhibit the SARS-CoV 3Clpro: HIV protease is a Asp protease and differs considerably from the Cys protease 3Clpro, but it also shares some common elements, such as a tetrahedral transition state and receptor pockets to recognize the amino acid side chains of the substrates. Given that SARS-CoV-2 and SARS-CoV share very high identical sequence in their 3CLpro, these HIV protease inhibitors are currently again repurposed for the treatment of COVID-19 (Chinese Clinical Trial Registry: ChiCTR2000029539).
 <xref rid="bib22" ref-type="bibr">22</xref>, 
 <xref rid="bib23" ref-type="bibr">23</xref>, 
 <xref rid="bib24" ref-type="bibr">24</xref>
</p>
